O’Malley L, Druce KL, Chanouzas D, et al. - This study seeks to acknowledge how fatigue changes over time following treatment initiation and to ascertain whether individuals with the poorest prognosis can be robustly distinguished. Researchers included a total of 149 patients with antibody–associated vasculitis (AAV) and new-onset disease recruited to 2 clinical trials and follow up period was 18 months.  They assessed fatigue at baseline and 6-month intervals applying the vitality domain of the Medical Outcomes Study Short Form-36 quality of life questionnaire and correlated to a cohort of 470 controls. At diagnosis, in patients, fatigue levels were worse compared with controls, with 46% of patients reporting severe fatigue. Fatigue levels were longitudinally assessed in patients with AAV. An important subgroup of patients reported persistently high levels of fatigue that did not change, although most individuals improved following treatment. Few clinical or laboratory markers identified these patients, implying alternative interventions specific for fatigue are needed.